B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates

Jj, Lefrére; Mariotti, Martine; Thauvin, M

doi:10.1016/s0140-6736(94)90993-8

Cited by 93 publications

(47 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the B19 antibody-negative period Parvo B19 levels can be as high as 10 12 genome equivalents/ml [20]. Lefrère et al [21] detected B19 DNA in 6/20 batches of plasma-derived, large-pool clotting factor concentrate inactivated with an organic solvent-detergent method.…”

Section: Discussionmentioning

confidence: 99%

High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

Mauser‐Bunschoten¹,

Zaaijer²,

Drimmelen³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products. Materials and Methods: To determine the prevalence of the corresponding antibody in patients with hemophilia A or B or von Willebrand’s disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children). Results: The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was a significantly lower incidence in patients who were rarely treated. Conclusion: Parvovirus B19 is frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission.

show abstract

Section: Discussionmentioning

confidence: 99%

High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

Mauser‐Bunschoten¹,

Zaaijer²,

Drimmelen³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…The advent of PCR has greatly increased the sensitivity of DNA detection in serum and tissue samples, although it possesses a great propensity for contamination (153,183,193,254,311,375). DNA may be detectable for extended periods of time in serum (54,218,254), synovial membranes (278), and BM (52), even in healthy individuals.…”

Section: Detection Of B19 Virusmentioning

confidence: 99%

Human Parvovirus B19

2002

View full text Add to dashboard Cite

Parvovirus B19 (B19) was discovered in 1974 and is the only member of the family Parvoviridae known to be pathogenic in humans. Despite the inability to propagate the virus in cell cultures, much has been learned about the pathophysiology of this virus, including the identification of the cellular receptor (P antigen), and the control of the virus by the immune system. B19 is widespread, and manifestations of infection vary with the immunologic and hematologic status of the host. In healthy immunocompetent individuals B19 is the cause of erythema infectiosum and, particularly in adults, acute symmetric polyarthropathy. Due to the tropism of B19 to erythroid progenitor cells, infection in individuals with an underlying hemolytic disorder causes transient aplastic crisis. In the immunocompromised host persistent B19 infection is manifested as pure red cell aplasia and chronic anemia. Likewise, the immature immune response of the fetus may render it susceptible to infection, leading to fetal death in utero, hydrops fetalis, or development of congenital anemia. B19 has also been suggested as the causative agent in a variety of clinical syndromes, but given the common nature, causality is often difficult to infer. Diagnosis is primarily based on detection of specific antibodies by enzyme-linked immunosorbent assay or detection of viral DNA by dot blot hybridization or PCR. Treatment of persistent infection with immunoglobulin reduces the viral load and results in a marked resolution of anemia. Vaccine phase I trials show promising results

show abstract

“…B19 is non-enveloped and thermostable and therefore difficult to inactivate by the standard inactivation methods (solvent-detergent, pasteurization) that are used during the manufacture of blood products. Recent studies have shown that B19 DNA sequences are present in a range of blood products [5,6]. Although B19 is normally spread via the respiratory route, parenteral transmission can occur through the administration of blood products made from plasma pools contaminated with B19 [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Saldanha

Lelie²,

et al. 2002

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives A collaborative study, involving 26 laboratories from 14 countries, was carried out in order to establish a World Health Organization (WHO) International Standard for human parvovirus B19 (B19) DNA nucleic acid amplification techniques (NAT). Materials and methodsFour samples: AA, BB (which were lyophilized), CC and DD (which were liquid preparations) were analysed using several different NAT assays. The mean B19 DNA content of each sample was determined for each laboratory using an end-point dilution method.Results There was good agreement between the overall mean 'equivalents'/ml obtained by the different assays. The mean log 10 'equivalents'/ml were 5·76 for sample AA, 5·73 for sample BB, 5·82 for sample CC and 7·70 for sample DD. The differences in titre among samples AA, BB and CC were not statistically significant, but the titre of DD was significantly higher.

show abstract

B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates

Cited by 93 publications

References 9 publications

High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

Human Parvovirus B19

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques

Contact Info

Product

Resources

About